Zafgen Inc (NASDAQ:ZFGN) Given Average Recommendation of “Hold” by Brokerages

Zafgen Inc (NASDAQ:ZFGN) has received an average rating of “Hold” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.10.

Several brokerages have recently commented on ZFGN. Piper Jaffray Companies lowered Mallinckrodt from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $39.00 to $9.00 in a research note on Thursday, May 30th. Wedbush reaffirmed a “buy” rating and issued a $6.00 price target on shares of Zafgen in a research note on Thursday, May 30th. Cowen reaffirmed a “hold” rating on shares of Zafgen in a research note on Thursday, May 30th. Roth Capital began coverage on Zafgen in a research note on Friday, April 26th. They issued a “buy” rating and a $8.00 price target on the stock. Finally, ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.

NASDAQ ZFGN traded down $0.01 on Friday, reaching $1.15. 43,561 shares of the company were exchanged, compared to its average volume of 385,953. The firm has a fifty day simple moving average of $1.34. The company has a market cap of $43.30 million, a PE ratio of -0.61 and a beta of -0.40. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.83 and a quick ratio of 7.83. Zafgen has a fifty-two week low of $1.13 and a fifty-two week high of $12.35.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.05. Research analysts anticipate that Zafgen will post -1.4 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. purchased a new stake in shares of Zafgen in the 4th quarter valued at $65,000. SG Americas Securities LLC purchased a new stake in shares of Zafgen in the 1st quarter valued at $43,000. Bank of America Corp DE raised its holdings in shares of Zafgen by 155.5% in the 4th quarter. Bank of America Corp DE now owns 19,909 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 12,116 shares during the period. Jane Street Group LLC purchased a new stake in shares of Zafgen in the 4th quarter valued at $99,000. Finally, Two Sigma Advisers LP raised its holdings in shares of Zafgen by 115.4% in the 4th quarter. Two Sigma Advisers LP now owns 30,800 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 16,500 shares during the period. 84.26% of the stock is currently owned by institutional investors and hedge funds.

Zafgen Company Profile

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Further Reading: Earnings Per Share (EPS)

Analyst Recommendations for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.